VisionAire 500K

Biocytogen’s Project Integrum Achieves Milestone Progress, Accelerating Antibody Business Growth

Retrieved on: 
Friday, August 18, 2023
Biotechnology, General Health, Other Health, Health, Pharmaceutical, Medication, VisionAire 500K, Growth, Spacecraft, HKEX, 1998 Pep Boys 400K, IND, Investment, Antibody, Restitutio ad integrum, Fine chemical, Vaccine

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) announced today that its Project Integrum has completed 2 core milestones, and its antibody business is now entering a new stage of rapid growth.

Key Points: 
  • Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) announced today that its Project Integrum has completed 2 core milestones, and its antibody business is now entering a new stage of rapid growth.
  • Project Integrum is a large-scale R&D project designed to discover novel therapeutic antibodies for more than 1000 druggable targets.
  • The rapid progress of the project has directly led to the exponential growth of Biocytogen’s antibody licensing and co-development business, with 50 antibody asset-based co-development/out-licensing/transfer agreements established, including partnerships with 6 multinational pharmaceutical companies.
  • As the number of co-development products entering clinical trials increases, Biocytogen's ongoing business growth will be fueled not only by upfront payments but also by milestone payments.

iSportsmanX: AcXess the Outdoors with Ease

Retrieved on: 
Thursday, December 8, 2022
U.S. Army Public Health Center, United States Department of Defense, U.S. Air Force aeronautical rating, Jack Hawkins (U.S. Marine Corps officer), Army National Guard, VisionAire 500K, ATV, Veteran, Hunting

In mid-December, iSportsman will elevate their dot-net site to offer users a modern, comprehensible, and interactive experience.

Key Points: 
  • In mid-December, iSportsman will elevate their dot-net site to offer users a modern, comprehensible, and interactive experience.
  • iSportsmanX is one of the many new features that will be available on the re-designed iSportsman website.
  • iSportsmanX is a free new service available to both iSportsman users and the public.
  • It is a search optimization tool created specifically to return results on outdoor activities.

Deep Bio Presents Research Results of AI-based Cancer Diagnosis and Prognosis at the AACR Annual Meeting 2022

Retrieved on: 
Monday, April 11, 2022
Risk, Adenocarcinoma, Medicine, Diagnosis, Medical device, IVD, Prostate, Stanford University School of Medicine, Survival, AACR, Research, Malignancy, Pathology, American Association, Workload, MFDS, Cancer, CEO, CTO, Marie Cassidy, 2021 Essex County Council election, Association, American Association for Cancer Research, Survival analysis, H&E, Prostate cancer, WSI, Ministry, VisionAire 500K, Breast cancer, AI, Deep learning, Patient, Prognosis, Algorithm, Medical imaging, Food

SEOUL, South Korea, April 11, 2022 /PRNewswire-PRWeb/ -- Deep Bio, a pioneer in medical AI for pathologic cancer diagnostics, presented five abstracts in regards to cancer diagnosis and prognosis of multiple cancer types using deep learning-based algorithms at the American Association for Cancer Research (AACR) 2022 which took place both in-person and virtually in New Orleans.

Key Points: 
  • SEOUL, South Korea, April 11, 2022 /PRNewswire-PRWeb/ -- Deep Bio, a pioneer in medical AI for pathologic cancer diagnostics, presented five abstracts in regards to cancer diagnosis and prognosis of multiple cancer types using deep learning-based algorithms at the American Association for Cancer Research (AACR) 2022 which took place both in-person and virtually in New Orleans.
  • Deep Bio also shared meaningful study results in prostate cancer, its core research area.
  • Tae-Yeong Kwak, the CTO of Deep Bio, said, "Prognosis analysis of cancer is crucial in that it directly affects patients' treatment and care plans.
  • "By presenting significant research results at this year's AACR, Deep Bio not only showcased its commitment to AI-based cancer diagnosis and digital pathology but also expanded its presence globally.

Deep Bio Presented Deep Learning-based Cancer Research at the USCAP 111th Annual Meeting

Retrieved on: 
Wednesday, March 23, 2022
Medicine, Diagnosis, Medical device, IVD, Prostate, Breast, Research, Pathology, Prognosis, Workload, MFDS, Cancer, CEO, CTO, Marie Cassidy, USCAP, United States and Canadian Academy of Pathology, Survival analysis, H&E, Prostate cancer, Breast cancer, Deep learning, Ministry, VisionAire 500K, Stanford University School of Medicine, Medical imaging, Food

The studies explore how deep learning can be utilized in cancer diagnosis, prognosis, and prediction of multiple cancer types, including prostate, breast, lungs, etc.

Key Points: 
  • The studies explore how deep learning can be utilized in cancer diagnosis, prognosis, and prediction of multiple cancer types, including prostate, breast, lungs, etc.
  • In particular, novel research studies such as "Deep Learning-based Automated Detection of Prostate Cancer Lesions in Hematoxylin Only Visualized Images" and "Breast Cancer Survival Analysis through the Extracted Feature from the Prostate Diagnosis Model" drew attention from the USCAP attendees.
  • About Deep Bio Deep Bio Inc. is an AI biotech company with in-house expertise in deep learning, pathology, life sciences, and pharmacotherapeutics.
  • Deep Bio is actively engaged in the research space and participating in ongoing collaborations with top US medical centers.

Deep Bio and Tribun Health Join Forces to Enhance Cancer Care with AI-Powered Digital Pathology

Retrieved on: 
Wednesday, December 1, 2021
Algorithm, Automation, Adoption, CEO, Prostate cancer, Prostate, Workload, Deep learning, AI, Industry, Acquisition, Diagnosis, Partnership, Cancer, IVD, Leadership, Laboratory, Ministry, Peer review, Prognosis, Medicine, IMS, TURP, Prostatectomy, Pathology, Medical device, VisionAire 500K, Macro, Marie Cassidy, Medical imaging

Under the agreement, the two companies will harness the power of AI in digital pathology to improve cancer patient care.

Key Points: 
  • Under the agreement, the two companies will harness the power of AI in digital pathology to improve cancer patient care.
  • DeepDx Prostate, Deep Bio's deep learning-based prostate cancer diagnostic support software, aids pathologists in making fast and consistent diagnostic decisions for prostate cancer.
  • Recently, Tribun Health unveiled the "Tribun Health Platform", with at its core, CaloPix, the gold standard in Image Management and analysis for pathology.
  • Deep Bio Inc. is an AI biotech company with in-house expertise in deep learning, pathology, life sciences, and pharmacotherapeutics.

Deep Bio Partners with Morphle Labs for Digital Pathology Image Analysis

Retrieved on: 
Thursday, October 28, 2021
Marie Cassidy, Workload, Diagnosis, Hospital, Prognosis, Cancer, Prostate, Deep learning, Pathology, CLIA, Partnership, Medicine, Patient, H&E, Social robot, Ministry, Software, Lists of countries and territories, Dr Lal PathLabs, AI, CEO, Laboratory, Solution, IVD, Prostate cancer, Medical device, VisionAire 500K, Robotics, Medical imaging

SEOUL, South Korea, Oct. 27, 2021 /PRNewswire-PRWeb/ -- Deep Bio, a pioneer in medical AI specialized for cancer diagnostics, announced a strategic relationship with a leading slide scanner manufacturer and digital pathology systems provider, Morphle Labs.

Key Points: 
  • SEOUL, South Korea, Oct. 27, 2021 /PRNewswire-PRWeb/ -- Deep Bio, a pioneer in medical AI specialized for cancer diagnostics, announced a strategic relationship with a leading slide scanner manufacturer and digital pathology systems provider, Morphle Labs.
  • With this partnership, Deep Bio's deep learning-based prostate cancer diagnosis support software DeepDx Prostate will now be available to pathologists through Morphle Lab's digital pathology platform.
  • Deep Bio Inc. is an AI biotech company with in-house expertise in deep learning, pathology, life sciences, and pharmacotherapeutics.
  • Morphle Lab's Inc. is a new-age Medical Robotics company designing and manufacturing state-of-the-art Whole Slide Scanners & Pathology Lab Automation Robotics.

Deep Bio and ARUP to Conduct a Prospective Study to Evaluate AI Performance in a Real-World Pathology Workflow

Retrieved on: 
Monday, October 25, 2021
Sun-woo Kim, Marie Cassidy, MD, Workload, Efficiency, Diagnosis, University, Prognosis, ARUP, Prostate, Deep learning, Medicine, Laboratory, Decision-making, H&E, MFDS, Doctor of Philosophy, Experimental pathology, CEO, Solution, IVD, Prostate cancer, Medical device, ARUP Laboratories, VisionAire 500K, Cohort study, Medical imaging

The company will conduct a prospective study to validate the performance of its AI-based prostate cancer diagnosis software, DeepDx Prostate, at ARUP Laboratories, a leading reference laboratory in the US.

Key Points: 
  • The company will conduct a prospective study to validate the performance of its AI-based prostate cancer diagnosis software, DeepDx Prostate, at ARUP Laboratories, a leading reference laboratory in the US.
  • This prospective study is significant in that it validates the overall performance of DeepDx Prostate on real-world patient data," stated Sun Woo Kim, the CEO of Deep Bio.
  • In addition to this study, Deep Bio and ARUP have plans to collaborate on other clinical research related to cancer diagnosis, prognosis, and prediction.
  • Deep Bio Inc. is an AI biotech company with in-house expertise in deep learning, pathology, life sciences, and pharmacotherapeutics.

Deep Bio's AI-based Antibody Optimization Platform Applied to Parkinson's Disease

Retrieved on: 
Friday, August 13, 2021
Time, Drug discovery, Prostate, Parkinson's disease, CEO, Pathology, University, Deep learning, Medicine, Partnership, Research, Laboratory, Antibody, Prognosis, Patient, VisionAire 500K, Medical device, Technology, H&E, AI, IVD, Diagnosis, MFDS, Workload, R, Marie Cassidy, Prostate cancer, Medical imaging

The R&D collaboration aims to find the most optimized antibody by applying Deep Bio's AI technology to promising candidates.

Key Points: 
  • The R&D collaboration aims to find the most optimized antibody by applying Deep Bio's AI technology to promising candidates.
  • The antibody under study, if successful, has the potential to become an effective treatment option for patients with Parkinson's disease.
  • Utilizing our AI-based algorithm will dramatically reduce the time and cost for drug optimization," said the CEO of Deep Bio.
  • Deep Bio Inc. is an AI biotech company with in-house expertise in deep learning, pathology, life sciences, and pharmacotherapeutics.